Clinically Validated Precision Oncology
Where Science Meets Hope Through
Personalized Cancer Treatment
Not every cancer is the same, neither are you
ChemoID helps oncologists find the right chemotherapy for your unique tumor
Precision medicine starts
with knowing your cancer
ChemoID is a clinically validated precision oncology test platform that enables oncologists to select the most effective chemotherapy for each patient. Supported by randomized clinical trials demonstrating increased overall survival, the test was granted FDA Breakthrough Device Designation for its potential to improve the standard of care.
ChemoID identifies therapies that specifically target the resistant cancer stem cells responsible for tumor recurrence and treatment failure, especially in aggressive and hard-to-treat cancers such as glioblastoma (GBM) and platinum-resistant ovarian cancer, while minimizing unnecessary toxicity and reducing overall healthcare costs.
ChemoID is a clinically validated precision oncology test platform that enables oncologists to select the most effective chemotherapy for each patient. Supported by randomized clinical trials demonstrating increased overall survival, the test was granted FDA Breakthrough Device Designation for its potential to improve the standard of care.
ChemoID identifies therapies that specifically target the resistant cancer stem cells responsible for tumor recurrence and treatment failure, especially in aggressive and hard-to-treat cancers such as glioblastoma (GBM) and platinum-resistant ovarian cancer, while minimizing unnecessary toxicity and reducing overall healthcare costs.
